Physician profile
John Patrick Mullally
NPI 1033105630
$11,258.93
in general payments reported to CMS, 2019-2025
59 companies · $1,899 in 2025
The $1,899 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,236 · 2020: $1,248 · 2021: $1,726 · 2022: $1,787 · 2023: $1,569 · 2024: $1,794 · 2025: $1,899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,262.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,541.41 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,128.28 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $810.12 | 2021-2025 | |
| Harmony Biosciences LLC | $697.29 | 2020-2025 | Wakix |
| Glaxosmithkline, LLC. | $656.87 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $516.46 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $493.35 | 2019-2024 | Jardiance, Tradjenta, Spiriva Respimat |
| Mylan Specialty L.P. | $475.43 | 2020-2024 | Yupelri |
| Abbvie INC. | $435.37 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $382.10 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Amgen INC. | $323.77 | 2019-2025 | Repatha, Repatha, Otezla |
| Viatris Specialty LLC | $238.49 | 2025 | Yupelri |
| Grifols USA, LLC | $235.12 | 2019-2025 | Prolastin-C Liquid |
| Astellas Pharma US INC | $208.72 | 2019-2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $207.91 | 2019-2023 | Trintellix |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $165.83 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $161.60 | 2022-2024 | Quviviq |
| Sanofi-Aventis U.S. LLC | $147.71 | 2020-2023 | |
| Shield Therapeutics INC | $143.59 | 2023-2024 | Accrufer |
| Pfizer INC. | $141.62 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $120.91 | 2019-2023 | |
| Amarin Pharma, INC. | $118.25 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $115.86 | 2019-2023 | Qelbree, Tlando, Xyosted |
| Alkermes, INC. | $114.39 | 2022-2023 | Aristada, Lybalvi |
| Antares Pharma, INC. | $113.21 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $112.64 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $111.75 | 2021-2025 | Caplyta |
| Jazz Pharmaceuticals INC. | $97.68 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $90.25 | 2019-2023 | Verquvo, Januvia, Belsomra |
| Eisai INC. | $85.05 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.81 | 2023-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $68.56 | 2024 | Voquezna |
| Biogen, INC. | $65.89 | 2020-2021 | |
| Tolmar, INC. | $57.57 | 2024-2025 | Jatenzo |
| Exact Sciences Corporation | $56.98 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $55.44 | 2022-2025 | Freestyle Libre 3 |
| Lundbeck LLC | $52.76 | 2022-2025 | Rexulti |
| Optinose US, INC. | $48.73 | 2024 | |
| Vanda Pharmaceuticals INC. | $48.24 | 2024-2025 | Fanapt |
| Halozyme INC | $46.41 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $45.92 | 2019-2020 | |
| Allergan, INC. | $45.91 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $41.81 | 2022-2023 | Livalo, Seglentis |
| Sumitomo Pharma America, INC. | $40.61 | 2025 | Gemtesa |
| Dexcom, INC. | $39.59 | 2021-2024 | Dexcom G6 Transmitter |
| Scilex Pharmaceuticals INC. | $38.50 | 2021 | |
| Xeris Pharmaceuticals, INC. | $34.42 | 2022 | |
| Nevro Corp. | $30.25 | 2022 | |
| Pulmonx Corporation | $23.60 | 2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Biohaven Pharmaceutical Holding Company Ltd. | $19.45 | 2022 | |
| Tris Pharma INC | $17.06 | 2024 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $16.25 | 2019 | |
| Ucb, INC. | $16.05 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $15.95 | 2024 | Opsumit, Uptravi |
| Almatica Pharma LLC | $15.50 | 2022 | |
| Corcept Therapeutics | $15.29 | 2025 | Korlym |
| Biohaven Pharmaceuticals, INC. | $14.42 | 2021 | |
| Circassia INC. | $11.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mullally listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.